Postpartum Twelve-hour Magnesium Sulphate for Preeclamptic Patients versus Twenty four-hour: A Randomized Controlled Trial
Badran, S., Fayek, A., Badran, E., Mahmoud, M., Yosef, A. (2024). Postpartum Twelve-hour Magnesium Sulphate for Preeclamptic Patients versus Twenty four-hour: A Randomized Controlled Trial. EKB Journal Management System, 28(2), 85-94. doi: 10.21608/egyfs.2024.349378
Sherif M. Badran; Ahmed Fayek; Esraa Badran; Mai Mahmoud; Ali Haroun Yosef. "Postpartum Twelve-hour Magnesium Sulphate for Preeclamptic Patients versus Twenty four-hour: A Randomized Controlled Trial". EKB Journal Management System, 28, 2, 2024, 85-94. doi: 10.21608/egyfs.2024.349378
Badran, S., Fayek, A., Badran, E., Mahmoud, M., Yosef, A. (2024). 'Postpartum Twelve-hour Magnesium Sulphate for Preeclamptic Patients versus Twenty four-hour: A Randomized Controlled Trial', EKB Journal Management System, 28(2), pp. 85-94. doi: 10.21608/egyfs.2024.349378
Badran, S., Fayek, A., Badran, E., Mahmoud, M., Yosef, A. Postpartum Twelve-hour Magnesium Sulphate for Preeclamptic Patients versus Twenty four-hour: A Randomized Controlled Trial. EKB Journal Management System, 2024; 28(2): 85-94. doi: 10.21608/egyfs.2024.349378

Postpartum Twelve-hour Magnesium Sulphate for Preeclamptic Patients versus Twenty four-hour: A Randomized Controlled Trial

The Egyptian Journal of Fertility of Sterility
Volume 28, Issue 2 - Serial Number 11106352, March 2024, Page 85-94  XML PDF (3.61 MB)
Document Type: Original Article
DOI: 10.21608/egyfs.2024.349378
View on SCiNiTO View on SCiNiTO
Authors
Sherif M. Badran email 1; Ahmed Fayek2; Esraa Badran3; Mai Mahmoud4; Ali Haroun Yosef3
11. Lecturer of Obstetrics and Gynecology, Faculty of Medicine, Assiut University
2Professor of Obstetrics and Gynecology, Faculty of Medicine, Assiut, University
3Assistant Professor of Obstetrics and Gynecology, Faculty of Medicine, Assiut University
44. Resident of Obstetrics and Gynecology, Women`s health hospital, Assiut University
Abstract
Background& aim: Eclampsia is one of the major complications for patients with severe pre-eclampsia. Magnesium sulphate has been used as gold standard preventive treatment for a long time. Currently there is no consensus on the optimum duration of administration with maximum efficacy and less adverse events. In postpartum women with severe pre-eclampsia, the effectiveness of taking magnesium sulphate for 12 hours versus 24 hours was compared in this research. The objective was to maximize anticonvulsant action effectiveness while reducing magnesium sulphate adverse effect exposure.
Patients and Methods: A total of 280 women with severe preeclampsia were enrolled in the study. Those patients were randomly subdivided into group 1): received Mgso4 12- hour after delivery maintained at 1g per hour for 12 h and group 2): received Mgso4 24-hour after delivery maintained at 1g per hour for 24 h. All participants were subjected to thorough evaluation with recording demographic, obstetric and peripartum data.
Results: Both groups had insignificant differences as regard demographic, obstetric, clinical, laboratory, antepartum and intrapartum data. Administration of 12-hour magnesium sulfate as much as 24-hour magnesium sulfate was effective regard occurrence of eclampsia. Postpartum 12 hours group had significantly shorter duration of urinary catheter insertion (15.07 ± 11.01 vs. 28.11 ± 11.49 (h); p< 0.001) and length of hospital stay (2.52 ± 1.57 vs. 3.56 ± 1.69 (day); p< 0.001). Only one woman in 12 hours group had oliguria. There were three women in 12 hours group required prolongation of magnesium sulphate intake beyond the planned time.  
Conclusion: twelve hours postpartum magnesium sulphate intake could be beneficial in women with severe preeclampsia as regard prevention of eclampsia with fewer side effects.
Keywords
Keyword: preeclampsia; magnesium sulphate; postpartum seizure; eclampsia; fits. 
Statistics
Article View: 31
PDF Download: 21